eFFECTOR Q1 net loss $8.8M; tomivosertib NSCLC fails; zotatifin advance

eFFECTOR Therapeutics, Inc.

2024-Q1 EPS reported -$2.16

Net loss of $8.8M ($2.16 per share) vs $10.0M ($5.96 per share) in Q1 2023.
Cash, equivalents, and short-term investments $25.4M at March 31, 2024; raised $15M in Jan 2024 registered direct offering.
Zotatifin ZFA triplet dose escalation at 0.14 mg/kg; RP2D expected H2 2024.
Tomivosertib KICKSTART trial in NSCLC: HR 0.62 (p=0.21), missed pre-specified 0.2 threshold; no path forward.
R&D expense decreased to $5.3M from $6.6M; cash runway into Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.75

eFFECTOR Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-135263

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.